Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docosahexaenoic acid in breath holding spells
NCT03965988Phase 3Recruiting
- Start
- May 2018
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breath-holding spells comparing Docosahexaenoic Acid with Placebo drug (2 arms). Primary endpoint: Frequency of the spells at 6 months. Started May 2018; status: recruiting.
02
Drugs
docosahexaenoic acid
03
Conditions
breath-holding spells
Beyond the preview
Go deeper on NCT03965988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965988.